The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Katunina E.A.

Department of Neurology, Neurosurgery and Medical Genetics of the Pirogov Russian National Research Medical University of the Ministry of Health of the Russia, Moscow, Russia

Avakian G.N.

Department of Neurology and Neurosurgery of the N.I. Pirogov Russian National Research Medical University

Titova N.V.

Kafedra nevrologii i neĭrokhirurgii lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Bezdol'nyĭ Iu.N.

Kafedra nevrologii i neĭrokhirurgii lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Malykhina E.A.

Kafedra nevrologii i neĭrokhirurgii lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Levodopa: from a discovery to new elaborations

Authors:

Katunina E.A., Avakian G.N., Titova N.V., Bezdol'nyĭ Iu.N., Malykhina E.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(4): 97‑103

Read: 17321 times

Download PDF (RU)
Contact the author
Table of contents

LEVODOPA: FROM A DISCOVERY TO NEW ELABORATIONS
LEVODOPA: FROM A DISCOVERY TO NEW ELABORATIONS

To cite this article:

Katunina EA, Avakian GN, Titova NV, Bezdol'nyĭ IuN, Malykhina EA. Levodopa: from a discovery to new elaborations. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(4):97‑103. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Art and creativity in Parkinson’s disease: the mysterious effe­cts of dopa­mine. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):13-20
Correlation of motor symptoms and cardiovascular dysfunction in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):59-67
Diagnosis of pathological and adaptive bala­nce changes in Parkinson’s disease to select a reha­bilitation program. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):88-94
Stress and sleep: Neurobiological aspe­cts and modern options of inso­mnia therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):14-21
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Sleep diso­rders in patients with Lewy body deme­ntia and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):81-87
Early diagnosis and effe­ctive therapy of diabetic poly­neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):62-68
Pharmacological treatment and prevention of ischemia-reperfusion syndrome in percutaneous coro­nary inte­rvention. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):191-200
Influence of griseofulvin on inte­stinal microbiota in the treatment of microsporia in rural children. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):185-190
Postoperative peri­tonitis: epidemiology, diagnosis, surgical treatment and prognosis. Piro­gov Russian Journal of Surgery. 2025;(6):104-111
Abstract:

Keywords:

Parkinson's disease
treatment
levodopa
Parkinson's disease
treatment
levodopa

Authors:

Katunina E.A.

Department of Neurology, Neurosurgery and Medical Genetics of the Pirogov Russian National Research Medical University of the Ministry of Health of the Russia, Moscow, Russia

Avakian G.N.

Department of Neurology and Neurosurgery of the N.I. Pirogov Russian National Research Medical University

Titova N.V.

Kafedra nevrologii i neĭrokhirurgii lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Bezdol'nyĭ Iu.N.

Kafedra nevrologii i neĭrokhirurgii lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Malykhina E.A.

Kafedra nevrologii i neĭrokhirurgii lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Close metadata

References:

  1. Kucheryanu V.G. Parkinsonizm: patogeneticheskie mekhanizmy i printsipy terapii: Avtoref. dis. ... d-ra med. nauk. M 2000; 48.
  2. Kucheryanu V.G., Kryzhanovskii T.N. Vliyanie glutamata i antagonistov NMDA-retseptorov na eksperimental'nyi parkinsonicheskii sindrom u krys. Byul eksper biol i med 2000; 130: 7: 20-23.
  3. Agid Y. Levodopa: is toxicity a myth? Neurology 1998; 50: 858-863.
  4. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Dis 2001; 16: 448-458.
  5. Antonini A., Isaias I.U., Canesi M. et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Dis 2007; 22: 1145-1149.
  6. Apaydin H., Ertan S., Ozekmerci S. Broad bean (Vicia faba) - a natural source of L-dopa -prolongs «on» periods in patients with Parkinson's disease who have «on-off» fluctuations. Mov Dis 2000; 15: 164-166.
  7. Barbeau A., Sourkes T.L., Murphy C.F. Les catecholamines de la maladie de Parkinson. In: J. Ajuriaguerra, ed. Monoamines et syste`me nerveau central. Geneve, George, Paris: Masson 1962; 247-262.
  8. Bennett J.P., Landow E.R., Dietrich S., Schuh L.A. Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Dis 1994; 9: 409-414.
  9. Bezard E., Brotchie J.M., Gross C.E. Pathophysiologyoflevodopa-induced dyskinesiain Parkinson's disease: opportunities foe novel treatments. Nat Rev Neurosci 2001; 2: 577-588.
  10. Birkmayer W., Hornykiewicz O. The effect of 3,4-dihydroxyphenylaline (-DOPA) on Parkinsonian akinesia. (In German) Wien. Klin Wochenschr 1961; 73: 787-788. Re-published in English translation in Parkinsonism and Related Disords 1998; 4: 59-60.
  11. Blunt S.B., Jenner P., Marsden C.D. Suppressive effect of L-dopa on dopamine cells remaining in the neurotoxin 6-hydroxydopamine. Mov Dis 1993; 8: 129-133.
  12. Carlsson A., Lindqvist M., Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957; 180: 1200.
  13. Cedarbaum J.M. Clinical pharmacokinetics of antiparkinsonian drugs. Clin Pharmacokinet 1987; 13: 141-178.
  14. Cedarbaum J.M., Olanow C.W. Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease. Neurology 1991; 41: 1567-1570.
  15. Colosimo C., Merello M., Hughes A. et al. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiat 1996; 61: 634-637.
  16. Cotzias G.C., Van Woert M.H., Schiffer L.M. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374-379.
  17. Danycz W., Parson's C.G., Komhuber J. et al. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci Biobehav Rev 1997; 21: 455-468.
  18. Datla K.P., Blunt S.B., Dexter D.T. Chronic L-dopa administration is not toxic to the remaining dopanainergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl3 nigrostrial lesions. Mov Dis 2001; 16: 424-434.
  19. Davis T.L., Brughitta G., Baronti F., Mouradian M.M. Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics. Neurology 1991; 41: 630-633.
  20. Ehringer H., Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in human brain: Their behaviour in extrapyramidal system diseases. (In German). KlinWochenschr 1960; 38: 1236-1239. Re-published in English translation in Parkinsonism and Related Disorders 1998; 4: 53-57.
  21. Eichhorn T.E., Schrag A., Trenkwalder C. et al. Effectiveness of slow release L-DOPA-benserazide in treatment of end-of-dose akinesia in Parkinson disease (in German). Nervenarzt 1995; 66: 933-941.
  22. Fahn S. Parkinson's disease, the effect of levodopa, and the ELLDOPA trial. Arch Neurol 1999; 56: 529-535.
  23. Fahn S. Parkinsonism. Complications of long-term levodopa therapy. In: L.P. Ronald, ed. Merritt's Textbook of Neurology. 9-th ed. New York: Williams&Wilkins 1995; 726.
  24. Fenelon G., Mahieux F., Huon R., Ziegler M. Hallucinations in Parkinson's disease. Prevalence, phenomenology and risk factors. Brain 2000; 123: 733-745.
  25. Fukuda T., Watabe K., Tanaka J. Effects of bromocriptine and/or L-dopa on neurons in substantia nigra of MPTP-treated C57BL/6 mice. Brain Res 1996; 728: 274-276.
  26. Gnanalingham K.K., Robertson R.G. Chronic continuous and intermittent 1-3,4-dihydroxyphenyIalanine treatments differentially affect basal ganglia unction in 6-hydroxydopamine lesioned rats - anautoradiographic study using Flunitrazepam. Neuroscience 1993; 57: 673-681.
  27. Gwinn-Hardy K., Evidente V.G., Waters C. et al. L-dopa slows the progression of familial parkinsonism. Lancet 1999; 353: 1850-1851.
  28. Hammerstad J.P., Woodward W.R., Nutt J.G. et al. Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients. Clin Neuropharmacol 1994; 17: 429-434.
  29. Han S.K., Mytilineau S., Cohen G. L-dopa upregulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996; 66: 501-510.
  30. Hefti P., Melamed E., Wurtman R.J. The site of dopamine formation in rat striatum after L-dopa admimsrtation. J Pharmacol Exp Ther 1981; 217: 189-197.
  31. Hornykiewicz O. L-Dopa: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids 2002; 23: 65-70.
  32. Jankovic J. Levodopa strengths and weaknesses. Neurology 2002; 58: 19-32.
  33. Jankovic J., Linfante I., Dawson L.E., Contant C. Young-onset versus late-onset Parkinson's disease: clinical features and disease progression. Ann Neurol 1997; 42: 448.
  34. Karstaedt P.J., Pincus J.H. Protein redistribution diet remains effective in patients with fluctuating parkinsonism. Arch Neurol 1992; 49: 149-151.
  35. Katzenschlager R., Lees A. Treatment of Parkinsons disease: levodopa as the first choice. J Neurol 2002; 249: 2: 19-24.
  36. Koller W.C., Hutton J.T., Tolosa E. et al. Immediate-release and controlled-release carbidopa/levodopa in Parkinson's disease: a 5-year randomized multicentrer study. Neurology 1999; 53: 1012-1019.
  37. Mizuno Y., Kondo T., Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995; 45: 3: 13-21.
  38. Murer M.G., Dziewczapolski G., Menalled L.B. et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998; 43: 561-575.
  39. Nutt J.G., Carter J.H., Van Houten L., Woodward W.R. Short- and long-duration responses to levodopa during the first year of levodopa therapy. Ann Neurol 1997; 42: 349-355.
  40. Nutt J.G., Fellman J.H. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984; 7: 35-49.
  41. Nyholm D., Nilsson Remahl A.I., Dizdar N. et al. Duodenal levodopa infusion monoterapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64: 216-23.
  42. Okazawa H., Murata M., Watanabe M. et al. Dopaminergic stimulation upregulates in vivo expression of brain derived neurotrophic factor (BDNF) in the striatum. FEBS Lett 1992; 313: 138-142.
  43. Olanow C.W. A rationale for dopamine agonists as primary therapy for Parkinson's disease. Can J Neurol Sci 1992; 19: 108-112.
  44. Olanow S.W., Obeso J.A. Preventing levodopa-indused dyskinesias. Ann Neurol 2000; 47: 1: 167-178.
  45. Olanow C.W. The scientific basis for the current treatment of Parkinson's disease. Ann Rev Med 2004; 55: 41-60.
  46. Perry T.L., Yong V.W., Foulkes J.G. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-dopa and carbidopa chronically. J Neurochem 1984; 43: 990-993.
  47. Pletscher A., DaPrada M. Pharmacotherapy of Parkinson's disease: research from 1960 to 1991. Acta Neurol Scand Suppl 1993; 146: 26-31.
  48. Poewe W. Dopamine agonists and the management of long-term complications in Parkinson's disease. In: Beyond the decade of the Brain. Eds.: C. Olanow, J. Obeso. Wells Medical Limited 1997; 2: 201-208.
  49. Quinn N.P. Classification of fluctuations in patients with Parkinson's disease. Neurology 1998; 51: 25-29.
  50. Rajput A.H., Fenton M.E., Birdi S., Macaulay R. Is levodopa toxic to human substantia nigra? Mov Dis 1997; 12: 634-638.
  51. Rinne J. O., Roytta M., Paljarvi L. Selegeline (deprenyl) treatment and death of nigral neurons in Parkinson's disease. Neurology 1991; 41: 859-861.
  52. Sage J.I., Mark M.H. The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease. Neurology 1992; 42: l: 23-28.
  53. Sano I., Gamo T., Kakimoto Y. et al. Distribution of catechol compounds in human brain. Biochim Biophys Acta 1959; 32: 586-587.
  54. Schrag A., Quinn N. Dyskinesia and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000; 123: 2297-2305.
  55. Shoulson I. Protective therapy for Parkinson's disease. In: Handbook of Parkinson's disease. Ed.: W.C. Koller. New York: Marcel Dekker 1992; 301-309.
  56. Syed N., Murphy J., Zimmerman T.Jr. et al. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Dis 1998; 13: 336-338.
  57. Tatton W.G., Ju W.Y., Holland D.P. et al. Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994; 63: 1572-1575.
  58. Tolosa E., Marti M.J., Valldeoriola F., Molinuevo J.L. History of levodopa and dopamine agonists in Parkinson's disease treatment. Neurology 1998; 50: 2-10.
  59. Verhagen Metman L., Konitsiotis S., Chase T.N. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Dis 2000; 15: 3-8.
  60. Yahr M.D., Duvoisin R.C., Schear M.J. et al. Treatment of parkinsonism with levodopa. Arch Neurol 1969; 21: 343-354.
  61. Zou L., Jankovic J., Rowe D.B. et al. Neuroprotection by pramipexole against dopamine and levodopa-induced cytotoxicity. Life Sci 1999; 64: 1275-1285.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.